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ABSTRACT 
EFFECTS OF INDOMETHACIN ON 
PROSTAGLANDIN E2 IN 7,12-DIMETHYLBENZ(A)ANTHRACENE 
INDUCED MAMMARY TUMORIGENESIS IN RATS FED DIFFERENT 
LEVELS OF fOLYUNSATURATED FAT 
Candace s. Smith 
Morehead State University, 1988 
The relationships between DMBA-induced mammary 
cancer, polyunsaturat~d fatty_ acids, -and PGE2_ as well as 
the effect of prostaglandin inhibitor indomethacin (IM). 
were examined. Those animals fed a diet containing 20% 
corn oil (HF) exhibited higher tumor burden, more rapid 
tumor growth and higher PGE2 levels than the rats fed 4% 
corn oil (LF). The addition of IM to the animals 
drinking water in the HF group caused a reduction in 
PGE2 levels. However, IM had little effect on their 
tumor growth. The addition of IM to the LF group 
reduced the percentage of tumor bearing rats by 23% to 
that of the LF group. Yet, the average tumor volume per 
rat was higher in all groups that received IM. 
Therefore, the conditions of this research demonstrated 
a mild role of PGE2 in the promotion of tumorigenesis in 
those groups not given IM treatment. 
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INTRODUCTION 
Investigations have identified a number of risk 
factors for the development of breast cancer, including 
early age at menarche, late age at first child birth, 
late age at menopause, and a family history of breast 
cancer. However, these factors do not explain the 
marked differences in breast cancer among women of 
different ethnic background around the world (·l) . The 
fact that one out of 10 American women develope breast 
cancer (2), and this type of cancer is the most frequent 
cause of cancer related death in these women brought 
about many studies in the last decade in the possible 
causes for the discrepancies (3). It was quickly 
determined that dietary fat played a major role. The 
United States has one of the highest dietary fat intakes 
per capita in the world and it has been estimated that 
the average American diet is composed of 20% fat (4). 
It has been shown that diet effects mammary 
tumors at two levels--the rate at which they form and 
the rate at which they grow (3). Yet, the mechanisms by 
which these rates are effected are still unclear. 
Several animal studies using a variety of both 
l 
spontaneous, translatable, and induced mammary tumors 
have demonstrated a direct correlation between a high 
fat diet and the growth of mammary tumors (4-17). 
2 
A possible mechanism being widely studied is the 
role of prostaglandins. Prostaglandins are lipid 
derived, therefore it was assumed that an increase in 
dietary fat would lead to an increase in prostaglandin 
production. Several laboratories have demonstrated this 
concept (4-31). It was through the use of prostaglandin 
inhibitors that a correlation between a reduction in the 
level of prostaglandins and tumor growth was first 
exhibited in several studies (4,5,11) while a study by 
Feldman and Hilf was not as successful (21). 
Diet and Cancer, 
The accepted mechanism for cancer development is· 
that the cancer is first initiated by some factor (i.e. 
chemical, ra~iation, virus) followed by a longer term 
promotional phase. Lipids have been suggested to be a 
tumor_ promoter. 
After it.was demonstrated that a high fat diet 
enhanced tumorigenesis, further study was needed to 
determine if some types of lipid were more effective at 
enhancing tumor growth than others. There appeared to 
be a tendency for diets high in polyunsaturated fat to 
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have higher tumor yields than saturated fat diets (1). 
It was further observed that a combination of a large 
amount of polyunsaturated fat with a small amount of 
saturated fat produced more mammary tumors than either 
source of fat (1). In general, diets rich in 
unsaturated fats (e.g. most vegetable oils) are more 
efficacious than diets rich in saturated fats (e.g, many 
animal fats) in the enhancement of the promotional stage 
of mammary tumorigenesis (9). Recent studies suggest 
that diets rich in saturated fatty acids, in contrast to 
unsaturated fatty acids, may be more important in the 
initiation stage of this tumorigenic process (9). 
Evidence now indicates that only a small amount of 
polyunsaturated fat is required to enhance the yield of 
mammary tumors. As little as 3% polyunsaturated fat 
when fed in a high saturated fat diet promoted tumor 
development as effectively as a diet containing four 
times as much (10). 
In a study by Hillyard and Abraham on the 
cellular elavation of tumors, it was determined that 
there was no difference in Gl,S,G2,M, or the total cell 
cycle time between the two diets. The same study 
reported that only about 40% of the tumor cells were 
dividing at any given time, and there was probably a 
constant interchange between the proliferating and 
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quiescent cell populations (15). These results show 
that the differe~ce in tumor weights between the two 
groups could not be accounted for by an effect on the 
fraction of cells dividing or a difference in cell cycle 
time. The size difference in the tumors were determined 
by the balance between tumor cell lysis and those tumor 
cells proliferating (15). The tumor cells provided a 
diet of saturated fat die faster than those provided a 
diet of polyunsaturated fat. Another.possible 
explanation is that the· cells promoted by a 
polyunsaturated fat diet started growing earlier. This 
is not the case. It was determined by Hillyard and 
Abraham that raptd tumor growth occurred at the same 
time if the animal received a fat free or 
polyunsaturated fat diet (6). The increase in 
polyunsaturated fat increases fluidity of the cell 
membrane, but this does not influence the susceptibility_ 
of the target cells to complement~mediated lysis (14). 
,Corn oil, contains_60% linoleic acid (11). 
Linoleic acid is the only pure polyunsaturated fatty 
acid known to promote mammary tumor growth (13). Rats 
with diets containing either 0.5% or 20% corn oil showed 
a tumor incidence of 20 to 28% with the low fat and 72 
to 76% with the high fat diet (12). Fish oil 
which also contains polyunsaturated fatty acids doesn't 
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have similar tumorigenic effects ( 10) .• Another fatty 
acid isolated from the seed oil of the columbine, is an 
18-carbon fatty acid with three double bonds. It 
contains two cis bonds at carbons 9 and 12 similar to 
linoleic acid and, in addition,. it possesses a double 
bond with a transconfiguration at the 5 position (13). 
This fatty acid with its configuration so similar to 
linoleic acid would be expected to enhance tumor growth 
to some extent but it does not. Rats fed this fatty acid 
do not convert it to linoleic acid to any appreciable 
degree (13). Stearate which contains 18 carbons but is 
saturated and oleate which contains a single double bond 
in the cis 9 position also do not enhance tumor growth 
(13). It was concluded from this data that 18 carbon 
fatty acids require two double bonds, as does linoleic 
acid, to be effective promoters. 
work from independent laboratories have shown an 
increase in the level of free fatty acids in tumor 
bearing animals and most of which is believed to be 
utilized by the tumor as a source of energy (7). The 
cholesterol levels, free and esterified, we~e also 
increased in the plasma of tumor bearing rats (7). A 
later study determined that the amount of linoleic acid 
in the total serum lipids closely reflects that of the 
diet (5). However this was not unexpected since 
6 
linoleic acid is an essential fatty acid. Another study 
demonstrated that the total serum lipid levels were 
higher ih animals fed a low fat diet.while it was the 
reverse in the high fat diet. A possible explanation is 
that a high fat diet would inhibit endogenous lipid 
synthesis (5). rt is well known that most animals 
convert linoleic acid to dihomo-~-linolate and 
arachidonate (see Fig. 1), precursors of prostaglahdins 
( 13) • Al though. die_tary linoleic acid correlates closely 
with total serum and tumor linoleic acid levels it does 
not equate with its metabolic product arachidonic acid 
in either tumor or serum lip~ds (5). 
If you use· a ratio of linoleic acid to 
arachidonic acid (A.A.) as a r01,1gh index to the degree 
of c:onversion of linoleic to A.A., it is highest in low 
- incidence groups and low in the high incidence groups 
· (corn oil).. Also when pure A.A. was added to the diet 
of tumor bearing rats it did not produ~e a significant 
increase in tumor mass (5,13). This would imply no 
direct relationship between dietary linoleic acid, A.A. 
and prostaglandins. It is possible that dietary A.A •. 
does not enter the same tissue pool as A.A. synthesis 
from linoleate ( 13) . 
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Figure l. Biosynthesis of prostaglandin precursors from 
linoleic acid. Taken from Martin (32). 
7,12-dimethvlbenze[a]anthracene (DMBA) 
The effects of dietary fats are strictly 
promotional, They may assist in the initiation phase 
but some type-~f carcinogen must be present for the 
induction of cancer. The two commonly used methods of 
induction of mammary cancer are radiation and 
hydrocarpons (16) . 
Polycyclic aromatic hydrocarbons (PAH) are 
widely distributed in environmental pollutants that have 
been linked to human tumorigenesis at a variety of 
anatomic sites. In animals, PAH are potent carcinogen!! 
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(8). In particular, the synthetic PAH, DMBA, is used to 
induce tumors of the mammary gland in experimental 
animals. Although DMBA is less widely distributed in 
the environment as compared to other related PAHs such 
as benzo(a)pyrene,·chrysene, and fluorunthene, its 
overall metabolism is similar (16). 
A high incidence of testicular cancer was 
observed in chimney sweeps in the early ·1s-oo 's. It was 
determined by Percivall Pott (1808) that it was due to a 
carcinogen found in the soot. After a series of 
research that encompassed four countries and required a 
162 years, aromatic hydrocarbons were isoiated and 
synthetic forms began being produced ( 16) ·. 
DMBA is one of the most potent carcinogens. Its 
structure is shown in figure 2. Carcinogenic 
hyd_rocarbons are flat molecules with conjugated double 
bonds systems and usually posses substituent groups of a 
special sort or an additional ring at a salient position 
on the molecule (16). 
There are three cancer prone areas in relation 
to DMBA: (1) mammary acinar, which line the lactiferous 
ducts (17), (2) hemopoietic tissue, and (3) fibroblasts 
(16). This results in several types of cancer: mammary 
adenocarcinoma, mammary fibroadenoma, leukemia, and ear 
duct cancer (16). However, mammary cancer is the most 
prevalent of the group (table l). 
Figure 2. The structure of DMBA. Taken·from Huggins 
( l 6) • 
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Adenocarcinomas consist of acini lined with many 
layers of epithelial cells arranged to form gland like 
structures with papillary projections (16). These 
tumors can arise any where in the mammary gland. In the 
·rat they have been found to occur from the neck to 
perineum. These tumors rarely metastasize and they 
bring about death by attaining gigantic size and 
invading adjacent tissue with consequent hemorrhage, 
necrosis, and ulceration (16). 
Table l. Incidence of neoplasms in rats fed DMBA. 
Taken from Huggins (16). 
TUMORS 
Mammary cancer 
Fibroadenoma 
Leukemia 
Ear duct cancer 
PERCENT 
100 
89 
3 
5 
10 
DMBA is taken up_by the liver metabolized and 
~xcreted into the bile or exported. Mammary tissue also 
has an ability to metabolize DMBA to a limited extent. 
The metabolic pathways consist primarily of oxygenation 
of the methyl groups and to a small extent of the ring 
structure (16). The main products of.the metabolism of 
DMBA by rat liver homogenates are the isomeric 
monohydroxymethyl derivatives: 7-hydroxymethyl-12-
methyl-BA and 7-methyl-12-hydroxymethyl-BA. Small 
amounts of phenols, diols, epoxides, and 
dihydrodihydroxy compounds as well as -7, -12-epidioxy-
7, 12-DMBA were detected (16). 
The electrophilic intermediates of the 
metabolism of DMBA are what bind to nucleophilic regions 
of DNA. The bay-region of syn- and anti-3,4-
11 
dihydrodiol-1,2 epoxides are considered to be the 
ultimate carcinogenic forms of.DMBA (8). These bind 
covalently to deoxyadenosine and deoxyguanosine residues 
of DNA (8). 
It was determined in 1971 that the number one 
chromosome of the rat was the most vulnerable, to DMBA 
(16). This high susceptibility to DMBA is exhibited in 
late interphase and prophase (16). In only 24 hours 
after injection of DMBA one half of the cells in 
metaphase in bone marrow have chromosomes with breaks 
and gaps (16). 
The tumors developed due to DMBA are excellent 
for scientific study of breast cancer. DMBA is not only 
metabolized in a similar fashion to naturally occurring 
PAHs. the superficial position of the tumors assures easy 
palpations, the end point i_s sharp, and they rarely 
metastasize (16). 
INDOMETHACIN (IM) 
Numerus laboratory and clinical studies have 
demonstrated that prostagl~ndins (PG) are involved in 
the initiation, development, and progression of some 
malignant diseases(S,12 14 20-31). Prostaglandin 
levels in both human and experimental carcinomas are 
consistently higher (19). Recent studies in animal 
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tumor models suggest that inhibitors of arachidonic acid 
(A.A.) metabolism such as indomethacin (IM) may inhibit 
tumor growth (5,12,20-28) although in some studies no 
antitumorigenic effects were observed (21), IM and 
other aspirin like compounds were recently studied by 
Karmali and Marsh (19). As seen in table 2, all of 
these compounds resulted in a reduction of tumor growth. 
Most chemopreventitive drugs have effects at one 
of three stages in tumor development (figure.·3). A.A. 
metabolic inhibitors work as suppressing agents (19). 
This has been demonstrated by the use of IM in several 
studies (5,8,11,12,15,20,22-31), while others who had a 
reduction in PGs saw no drop in tumor burden (21). In 
fact, the presence of IM in the diet has been shown to 
suppress tumor growth in animals fed a high fat diet, to 
1/3 the size of tumors· of high fat control rats ( 11). 
It was demonstrated that IM does not effect mammary 
tumor cell proliferation in vitro whereas it reduces 
the growth rate of the same neoplasms in vivo (15). It 
is therefore evident that the products of A.A. 
metabolism help in tumor promotion. One of the products 
~ of the pathway inhibited by indomethacin 
(cyclooxygenase) are PGEs. Their role in the bodies 
immunological system warranted research to determine 
their function in the relationship between a high fat 
diet and mammary cancer. 
IM treatment which inhibits the conversion of 
A.A. to PGs; could be expected to cause an accumulation 
in PG precursors in the·membrane. This however, is not 
the case, as demonstrated in a recent study by Feldman 
and Hilf (21). In addition to the direct activity of IM 
on prostaglandins synthesis, this inhibitor of the 
cyclooxygenase pathway can lead to increased synthetic 
activity of the lipo_xygenase pathway which has products 
that are reported to stimulate natural killer (NK) cell 
activity (27). The products of the lipoxygenase pathway 
are leuoktrienes so named because the compounds were 
first detected in leukocytes. ( 34) . 
TABLE 2. Mammary tumor growth in rats treated with 
cyclooxygenase inhibitors. Taken from Karmali and 
Marsh (19). 
Treatment .:Tumor weight in grams 
Control 2.49 
Indomethacin 1.96 
Ibuprofen 1.96 
Flurbiprofen 1.71 
CATEGORY OF 
INHIBITORS 
Inhibitors Preventing 
Formation of Carcinogens 
Blocking Agents 
Suppressing Agents 
14 
SEQUENCE LEADING 
TO NEOPLASIA 
Precursor Compounds 
t 
Carcinogenic Compounds 
l 
Reactions With 
Cellular .Targets 
l 
Neoplastic 
Manifestations 
FIGURE 3, Classification of chemopreventive agents. 
Taken from Wattenberg (18). 
Prosta·glandin E2 
The major rate limiting factor for PG synthesis 
is the availability of the fatty c:icid precursor (32). 
Cells usually contain substantial quantities of enzymes 
in the active form, but they sequester the fatty acid in 
the membrane phospholipids and in cholesteroyl esters, 
triacylglycerols, and lipoprotiens. Phospholipases, 
cholesterol esterases, triglycerides, lipases, and 
lipoprotein lipases that catalyze hydrolysis of the 
lipids can be activated by·numerus "non-specific" 
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factors. These include mechanical pressure, hypoxia, 
temperature chan~es and mild trauma (32). 
The activation of these enzymes stimulate the 
release of a 20 carbon fatty acid, arachidonic acid, 
which is metabolized into a variety of active mediators. 
The initial enzymes, cyclooxygenase and lipoxygenase, 
that convert A.A. to its mediators are constitutively 
active within cells (33). Thus three main groups of 
derivatives- the prostaglandins, the thromboxanes, and 
the leukotrienes- are formed ( 34). Prostaglandins and 
thromboxanes are formed via the cyclooxygenase pathway 
(figure 4). It is this pathway that is i~hibited by 
aspirin and aspirin like drugs such as indomethacin 
(IM). These non-steroidal anti-inflammatory drugs 
inhibit PGs and thromboxanes by either binding to or 
covalently modifying the protein region near the heme 
unit of the cyclooxygenase enzyme (35). 
A cyclooxygenase enzyme binds to a cytochro~e.b-. 
like hemoprotein cofactor (mw=70,000), which is readily 
lost, and in addition requires a nonheme iron which 
catalyzes the formation of PGG2 from A.A. (35). 
Prostaglandin G2 is a highly unstable endoperoxide that 
is rapidly converted to PGH2. The cyclooxygenase also 
catalyzes the second reaction, and the enzyme is 
therefore known as the "prostaglandin synthetase 
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system". The cyclooxygenase additionally catalyzes its 
own destruction and thereby limits PGG production after 
a time. The fate of PGG depends on the cell type. In 
most parts of the body a PGE isomerase catalyzes the 
formation of PGE (32). It is this particular PG that 
cancer researchers believe to be involved in the 
enhancement of cancer. 
The actions of PGs are executed through specific 
membrane bound receptors (36), which interact in complex 
ways with other regulators. These include cAMP, cGMP, 
Ca++, calmodulin, phospholipids, neurotransmitters, 
growth-promoting hormones, and kinase C (32j. 
Investigators have shown that PGs, particularly of the 
E-series, stimulate membrane bound adenylate cyclase in 
mammary tissue, therefore elevating cAMP levels (36). 
The same mechanism by which retioniods are believed to 
inhibit tumor growth (37). Thus, the concentration of 
the cAMP may play a role in determining the effect 
brought about. PGEs have a ·short half life. 
structurally, they have a ketone at carbon 9 and an 
alcohol at position 11 (figure 5). 
It has become increasingly apparent that among 
human peripheral blood mononuclear cells only the 
monocyte-macrophage and not T cells or B cells have the 
ability ·to produce these PGs (38), It is believed that 
Liporotein 
PG62 
Phospholipid ,,,.._etf!: 
:.e 
_., 
~ 
:: 
"' :a 
c:, 
PGD2 
Phosph 
HHT-,.MOA 
,,,e 
,._,ii> 
e"' 
Cholesterol 
ester 
' 
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Triacylglycerol 
PGl2 
t 
6-ke10-?Gi" ,a 
Figure 4. .. Sources of arachidonate and metabolites of 
the cyclooxygenase pathway. Taken from. Martin (32) 
18. 
the PGEs secreted by natural killer suppressor cells of 
the monocyte-macrophage lineage inactivate natural 
killer cells (23-25,38). If this is true, host 
macrophages may promote metas~asis by PG mediated 
inactivation of natural killer cells (23). 
Q Q o qH Q qH 
tc<x tc <=rtr·tc 
a · : I -
OH OH 
A B C D . e i;.. 
Q . 
-PiJ ~ 
C,H,, 
' 
' ' OH OH 
0 r. 1, J-r•""=/~H '1,CCJ:H 
~H11 
' 
' ' OH Oh 
-~ 
' ' 
' ' OH OH 
PG£, . PGE1 
Figure S. Structure and nomenclature of the classical 
prostaglandins. · Taken from Caton and Hart (36). 
This suppression may have its effect at one or 
all of the following steps: (l) development of the 
lytic function (activation process); (2) the recycling 
function of the activated cells, and (3) the killer 
function of the activated cells. PGs have also been 
demonstrated to suppress antibody formation, lymphokine 
production and T cell cytotoxici ty ( 25) .. 
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There appears a strong correlation between PG 
levels and metastasis. Whatever the size of the lesion, 
a high PG level was found associated with a marked 
increase in axillary lymph node metastasis in human 
breast cancer (26) and in animal models (27). 
While T cells, activated macrophages and NK 
cells have all been considered to play a role in 
metastasis, the role of the latter two cell classes 
appears particularly appealing because they do not 
require the fine antigenic specificity or memory 
response obligatory for T cell function and thus may be 
able to respond to a broad spectrum of tumors and may be 
more amenable to therapeutic manipulations (23). 
It has recently been reported that during 
development of transplanted or spontaneous tumors in 
mice, the NK activity declines with increasing tumor 
burden. It appears that NK cells are inactivated not 
reduced in number. This inactivation may be mediated 
via PGs (23). Although significant inhibition of 
cytotoxicity by PGs was observed in experiments a 
complete suppression of NK activity was never obtained 
(25). This finding may reflect the existence of a 
subpopulation of NK cells that lack PG receptors, and 
are therefore resistant to PG mediated inhibition (25). 
IM and its antiaggratory action would prevent 
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tumor cells form sticking to the endothilial wall of the 
circulatory system and as such reduce the formation of 
new tumors. In this respect it is also important to 
consider the direct aggregatory of tumor cells on 
platelets (by means of release of thromboxane) and on 
vasoconstriction (27,39). The concept that PGs and 
related metabolites of A.A. are local regulators of the 
microcirculation is one that has been investigated 
extensively for the past several years. It is based on 
the observations that the adminstration of locally 
synthesized PGs are capable of profoundly changing 
microvascular tone and various vascular beds (39). In 
this relation PGEs are vasodilators therefore it is easy 
to see how PGEs could enhance metastasis. 
The effect of PGs on the immune response appears 
to follow a bell shaped dose response relationship. Low 
levels of PGs are required to initiate the immune 
response. This was demonstrated by the fact that adding 
anti-PGE2 inhibited cell mediated immunity (21). When 
the PGE2 concentration was high it inhibited the same 
response (21). The question still remains whether it is 
the absolute level of PGE or the proportional decrease 
(21). As more and more research data are brought 
forward it will become more clear how PGEs and dietary 
fat increase tumor growth. Yet, some areas are still 
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inconclusive. Ho'w PGs control the immune system? Why 
dietary fat and ~he formation of A.A. are not 
correlated? How they increase metastasis? These and 
several other questions will have to be answered before 
the relationship between dietary fat and mammary cancer 
can be understood. 
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Research Objectives 
In this study young virgin female rats were fed 
diets of different levels of polyunsaturated fat and 
then given IM to reduce PGE levels. Testing of the 
following hypothesis was accomplished by examination of 
tumor number, tumor burden, percentage of tumor bearing 
rats per group, PGE2 levels, and tumor occurence. 
Diet 
A high level of polyunsaturated fat in the diet 
and its ·relationship to mammary cancer has been observed 
in several studies (4-16). Its role in the increase of 
PG levels is still being widely studied. 
It was hypothesized that those animals fed a 
high fat diet would show an increase in tumor number, 
tumor burden, percentage of tumor bearing rats, PGE2 
levels, and have a later time of occurence. 
Indomethacin 
This nonsteroidal anti-innlammatory agent has 
not only been demonstrated to reduce PGE2 levels, but 
also tumorigenesis (12-13). 
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It was hypothesized that those animals given IM 
would show a decrease in PGE2 levels, tumor number, 
percentage of tumor bearing rats, tumor burden, tumor 
size andhave a earlier time of occurence. 
PGE2 
The effects of PGE on the immune system of tumor 
bearing rats have only recently been demonstrated (4-
31). These changes in the immune system would cause a 
decrease in survival chances. 
It was hypothesized that animals with high PGE2 
levels would show an increase in tumor burden, tumor 
number, percentage of tumor bearing rats and have an 
earlier time of tumor occurence. 
MATERIALS AND METHOD 
Animal Treatment 
Female Sprague-Dawley rats were obtained from 
Harlen Sprague-Dawely Inc., Indianapolis, Indiana. The 
rats were housed in stainless steel cagJs with one rat 
per cage in a temperature• and light controlled room. 
Food and water were available ad libitum. - The rats were 
assigned to one of four groups --two_experimental: IM 
high fat (HFI) and IM low fat (LFI) and two control:high 
fat (HF) and low fat (LF). The animals were then placed 
on either a high or low polyunsaturated fat ··diet 
containing 20% or 4% fat diet respectively. The common 
components in both diets were in percentage by weight 
and both diets were equal in calories (table 3). The 
casein,· cellulose, minerals, vitamins, methionine, and 
choline were purchased from U.S. Biochemical, Cleveland, 
·Ohio. The corn oil and sugar were purchased locally . 
. 
IM (Sigma Chemical Company, st. Louis, MO) was dissolved 
in 10 ml of ethanol and diluted with water to give a 
final concentration of .025mg/ml. 
At 50 days of age all animals received a single 
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10mg dose of DMBA in 1ml of corn oil by intragastric 
administration. One month later all rats were being 
palpated weekly. At day 89 all of the animals were 
decapitated and at the time of sacrifice blood was 
collected in polypropylene tubes and clotted blood was 
centrifuged at 3000xg for 10 minutes, serum was removed, 
and stored at O degrees centigrade. All of the tumors 
were measured in 3 dimensions (LxWxH) with calipers. 
One tumor was dissected from each tumor bearing rat, 
frozen in dry ice-acetone mixture, and stored at -80 
degrees centigrade. 
Table 3. Diet concentration by percentage 
COMPONENT HIGH FAT DIET LOW FAT DIET 
Casein 21.6% 21.7% 
Sucrose 21.9% 57.0% 
Corn oil 19.4% 3.9% 
Cellulose 31.8% 12.1% 
Minerals 3.8% 3.8% 
Vitamins 1.0% 1.0% 
Methionine 0.3% 0.3% 
Choline 0.2% 0.2% 
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PGE2 Extraction and Determination 
Tumors were homogenized 1 _to 5 (g/ml) in Kerbs 
Ringer Bicarbonate Glucose and centrifuged at 3500xg at 
4 degrees centigrade. The homogenates and plasma 
samples were reduced to pH 4 with lN HCL. The 
prostaglandins were then extracted 1:10 with ethyl 
acetate (39). The samples were then dried with a vacuum 
pump and resuspended 1:1 in assay buffer. PGE2 
concentrations were determined with a prostaglandin E2 
[125I] RIA kit (Dupont Biomedical Products, Boston, MA). 
Buffer and antiserum were· added to each sample and 
incubated 24 hours. The precipitating solution was 
added and the samples were centrifuged at 2000xg at 4 
degree centigrade. The pellets were resuspended in 5ml 
of Ready Safe Scintillation Fluid and read in a Beckman 
Scintillation Counter model LS 801. 
statistical Analysis 
An un-paired t-test was used to determine the 
significance of the results (P>.OS). 
RESULTS AND DISCUSSION 
Rats exposed to DMBA at day 50 developed tumors 
89 days later on all dietary regimes (table 4). A lower 
percentage of rats developed tumors in both LFI and LFC 
when compared to their experimental groups. The 
indomethacin did not reduce the percentage of rats 
developing tumors in the groups receiving ·the HF diet, 
but was somewhat effective in reducing the number of 
rats with tumors from 73% to 50% on low fat diets. The 
indomethacin rats also developed tumors later than their 
controls (table 4). 
Table 4. Comparison between groups, percentage of rats 
with tumors, body weight at death, and first day of 
tumor occurrence in relation to palpation schedule 
GROUP 
LFC 
HFC 
LFI 
HFI 
BODY WT. PERCENTAGE FIRST DAY OF OCCURRENCE 
249 73% 76 
240 82% 68 
222(a) 50% 8S(b) 
230(a) 91% 7l(b) 
a Statistically different from others, p>o.os. 
b Statistically different from others, p>0.05. 
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A comparison of body weights at death can be 
seen in table 4. Those rats in the experimental groups 
had body weights that were significantly lower. This 
could be due to IMs toxic effects in the gastric system 
(4,20,23). A study done by McCormick and Wilson 
demonstrated that these effects can be counteracted by 
certain antioxidants like butlyated hydroxytolune (20). 
Total tumor number per dietary group and tumor 
number per rat were reduced in the LFC and LFI groups 
(table 5). Tumor number per tumor bearing rat was lower 
only in the LFC group (table 5). The data presented in 
tables 4 and 5 disagree with the hypothesis statement 
that the effects of indomethacin would be demonstrated 
equally in both experimental groups. Its effects were 
more profound in the low fat group. 
A distinct difference can be seen in 
relationship to type of diet, total tumor burden, and 
average tumor burden per rat (figures 6 and 7). In both 
cases the low fat diets were lower, which agrees with 
the hypothesis that the low fat diet will reduce 
tumorigenesis at all phases of the study. The 
comparisons between the control groups and the 
experimental groups were not significant, but the 
experimental groups were somewhat higher. 
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Table 5. Comparison between groups, total tumors, tumor 
number per rat and tumor number per tumor bearing rat. 
GROUP TOTAL TUMOR ii TUMOR ii PER 
TUMORS PER RAT TUMOR BEARING RAT 
LFC ll(a) 1 1.4 
HFC 23 2.1 2.5 
LFI 15(a) 1.3 2.5 
HFI 21 1. 9 2.1 
a statistically different from high fat diet, p>0.05. 
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Figure 6, Total tumor burden per group. Showing a 
significant difference between the two diets, p>0.05. 
30 
31 
13 
12 
II 
10 
9 
8 ,.. 
~ 
'C 
l'l C 
Eg 7 
EJ 0 6 
!: 
I-
V 
5 
4 
3 
2 
LFC HFC l.FI HFl 
ffilXJPS 
Figure 7. Average tumor burden per rat. Showing a 
significant difference between the two diets, p>0.05. 
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The PGE2 assay was inconclusive. Yet, certain 
trends could be see_n in the average no.rmalized percent 
of PGE2 [Il25] bound. Since the assay required the use 
of a competitive binding, a inverse relationship exists 
between percent bound and PGE2 levels. Thus, the higher 
the level of PGE2 [Il25] bound the lower the 
concentration of PGE2 in the sample (table 6). In the 
plasma samples the LFC group had higher PG levels than 
the LFI group. A similar tend could be seen in the 
comparison of the HFC and HFI groups. The PGE2 
concentrations in the tumors appeared higher than those 
in the plasma samples but this could be due to a 
discrepancy in protocol. The same trends were observed 
in relation to experimental and control groups as seen 
in the plasma samples. IM was again successful in the 
reduction of PGE2 levels. 
In summary, the low fat diet reduced the 
percentage of tumor bearing rats, deterred tumor 
formation by a number of days, reduced the total tumors 
per group and per rat, and lowered the tumor burden 
(tables 4 and 5, figures 6 and 7 ) • These reductions may 
have been brought about by the effects of lower PGE2 
levels in those rats fed a low fat diet ( table 6) . 
IM treatment also deterred tumor formation, 
decreased the percentage of tumor bearing rats, and 
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lowered animal body weights at death (table 4). This 
treatment had no significant effect on total tumor 
numbers or tumor burden (table 5, figures 6 and 7). 
Table 6. Normalized percent bound of PGE2 [Il25] 
SAMPLE 
TUMORS 
PLASMA 
LFC 
5.5 
21.8 
. HFC 
4.7 
13.4 
LFI 
10.7(a) 
35.0(b) 
HFI 
6.4 
16.4 
a Statistically different from the other groups, p>.05. 
b statistically different from the other groups, p>.05. 
Therefore, it was demonstrated that 
indomethacin reduces the number of tumor bearing rats, 
but does not reduce the size of the tumors which do 
occur. A study on human breast cancer and PG 
concentration indicated that PG production was higher in 
small tumors and in tumors with a high cellular density 
(26). That was not demonstrated in. this study. The LFC 
group had lower tumor number per tumor bearing rat 
(figure 6) and lower average tumor volume (figure 7) 
than the HFC, but the LFC tumor PGE2 levels were lower. 
It would be interesting to see the influence of 
anti-inflammatory steroids on DMBA induced mammary 
tumors. These steroids act by inhibiting the release of 
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A.A., they prevent formation not only of PGs and 
thromboxanes, but also leukotrienes (34). 
Corticosteriods have side effects, but a new dual 5-
lipooxygenase/cyclooxygenase inhibitor "L-652,343" is 
being studied for use in hypersensitivity disorders, 
does not (41). The outcome of a study using this new 
molecule and mammary cancer would give an answer to the 
question of the role of lipoxygenase pathway in this 
type of cancer. 
In the battle, to determine the concentration at 
which PGEs initiate or deter the immune system, PGE 
agonist like 16-dimethyl PGE2 could be used (42,43), 
while the role of leukotrienes could be determined by 
using there antagonist and agonist (44). Experiments 
using these molecules would help define the roles of 
PGEs and leukotrienes in the relationship between a high 
fat diet and mammary cancer 
Although a large amount of research has been 
performed linking PGE2 and mammary cancer it will 
require several more years before the true mechanism, by 
which PGE2 and dietary polyunsaturated fat cause mammary 
cancer, will be completely understood. Until that time 
IM will probably be widely used as a chemopreventative 
drug either by itself or in combination therapy. It is 
not completely known if the drug works via PG reduction 
35. 
or increasing the levels of leukotrienes, but what is 
important to cancer research is the IM reduces 
tumorigenesis in relation to certain types of diet, 
particular~y a diet low in polyunsaturated fatty acids 
as demonstrated here. 
LITERATURE CITED 
l Hirohata T., Nonura AMY, Hankin JH, Kolonel LN, -Lee 
J: An epodemiologic study on the association 
between diet and· breast_ cancer. JNCI 78: 595-600, 
1987. 
2 American Cancer society: Breast cancer. 1986 
Cancer Facts and Figures. American Cancer 
Society\New York, N.Y. 10, 1986. 
3 Abraham S, Faulkin LJ, Hillyard LA, Mitchell DJ: 
Effect of dietary fat on tumorigenesis in the mouse 
mammary gland. JNCI 72:1421-1425, 1984. 
4 King M, Bailey DM, Gibson DD, Pitha JV, Mccay PB: 
Incidence and growth.of mammary tumors induced by 
7,12-dimethyl[a]anthracene as related to the 
dietary content of fat and antioxidant. JNCI 
63:657-663, 1979. 
5 Cohen LA, Thompson DO, Choi K, Karmali AA, Rose DP: 
~ietary fat and mammary cancer II. Modulation of 
serum and tumor lipid composition and tumor 
prostaglandins by different dietary fats: 
Association with tumor incidence patterns. JNCI 
77:43-50, 1986. 
6 Hillyard LA, Abraham S: Effect of dietary 
polyunsaturated fatty acids on growth of mammary 
adenocarcinomas in mice and rats. Cancer Res 39 
4430-4437, 1979. 
7 El-Khatib SM, Cora EM: Role of high fat diet in 
tumorigenesis in C57BL/l mice. JNCI 66:297-301, 
1981. 
8 Singletary KW, Milner JA: Prior protein dietary 
intake and DNA-binding of 7,12-DMBA metabolites 
formed by isolated rat hepatocytes. JNCI 78:727-
733, 1987. 
36 
37 
9 Welsch CW: Enhancement of mammary tumorigenesis by 
dietary fat: Review of potential mechanisms. Am J 
Clin Nutr 45 192-202, 1987. 
10 Hopkins GJ, Kennedy TG, Carroll KK: 
Polyunsaturated fatty acids as promoters of mammary 
carcinogenesis induced in sprague-dawley rats by 
7,12-DMBA. JNCI 66:517-522, 1981. 
11 Carter AC, Milholland RJ, Shea W, Margot M: Effect 
of the prostaglandin synthetase inhibitor 
indomethacin on 7,12-dimethylbenz(a)anthracene-
induced mammary tumorigenesis in rats fed different 
levels of fat. Cancer Res 43:3559-3562, 1983. 
12 Kollmorgen GM, King MM, Kosanke SD, Do C: 
Influence of dietary fat and indomethacin on the_ 
growth of transplantable mammary tumors in rats. 
Canter Res 43:4714-4719, 1983. · 
13 Abraham S, Hillyard LA: Effect of dietary 18-
carbon fatty acids on growth of transplantable 
mammary adenocarcinomas in mice. JNCI 71:601-605, 
1983. 
14 Erickson KL: Mechanisms of dietary fat modulaion 
of tumoigenesis: Changes in immune response. 
Dietary Fat and Cancer 555-586, 1986. 
15 
16 
Gabor H, Hillyard LA, Abraham S: Effect of dietary 
fat on growth kinetics of transplantable mammary 
adenocarcinoma in BALB/c mice. JNCI 74:1299-1305, 
1985. 
Huggins 
Cancer. 
London, 
CB: Ex erimental 
The Universiy o 
1979. 
Leukemia and Mammar 
Chicago Press Chicago and 
17 Junqueira LC, Carneiro J, Long JA: The female 
reproductive system. Basic Histology. Lange 
Medical Puplications\Los Altos, CA., 508-509, 1986. 
18 Wattenberg LW: Chemoprevention of cancer. cancer 
Res 45:1-8, 1985. 
19 Karmali RA, Marsh J: Antitumor activity in a rat 
mammary adenocarcinma: The effect of cyclooxygenase 
inhibitors and immunization against prostaglandin 
E2. The Department of Nutrition. University of 
Rutgers New Jersey\New_Brunswick,N.J., 11-14, 1985. 
20 McCormick DL, Wilson AM: Combination 
chemoprevention of rat mammary carcinogenesis by 
indomethacin and butylated hydoxytolune. Cancer 
Res 46:3907-3911, 1986. 
21 Feldman Jm, Hilf R: Failure of indomethacin to 
inhibit growth of the R3230AC mammary tumor in 
rats. JNCI 75:751-756, 1985. 
22 McCormick DL, Madigan MJ, Moon RC: Modulation of 
rat mammary carcinogenesis by indomthacin. Cancer 
Res 45:1803-1808, 1985. 
23 Lala PK, Parhar RS, Singh P: Indometacin therapy 
abogates the prostaglandin-mediated suppression of 
natural killer activity in tumor-bearing mice and 
prevents tumor metastasis. Cell Immun 99:108-118, 
1986. 
24 Leung KH, Ip MM: Effect of dietary polyunsaturated 
fat and 7 ,12-dimethylbenz.(a)-anthracene on rat 
splenic natural killer cells and prostaglandin E 
synthesis. Cancer Immunol Immunother 21:161-163, 
1986. 
25 Brunda MJ, Herberman RB, Holden HT: Inhibition of 
murine natural killer cell activity by 
prostaglandins. J Immun 124:2682-2687, 1980. 
- 26 Rolland ·PR,--Marti:n- PM~~-Jacquemier J, Rolland AM, 
Toga M: Prostaglandin in human breast cancer: 
Evidence suggesting an elvated prostaglandin 
production is a marker of high metastatic potential 
for neoplastic cells. JNCI 64:1061-1069, 1980. 
27 Fulton AM: Interactions of natural effector cells 
and prostaglandins in the control of metasta.sis. 
JNCI 7:735-741, 1987. 
28 Lynch NR, Castes M, Astoin M, Salomon JC: 
Mechanism of inhibition of tumor growth by aspirin 
and indomethacin. Br J Cancer 3~:503-511, 1978. 
29 Kort WJ, Hulsman LOM, van Schalkwijk WP, Weijma IM, 
Zondervan PE, Westbroek DL: Reductive effect of 
aspirin teatment on primary tumor growth and 
metastasis of implanted fibrosarcoma in rats. JNCI 
76:711-716, 1986. 
30 Bennett A, Berstock DA, Carroll MA, Stamford IF, 
Wilson AJ: Breast cancer; its recurrence and 
patient survival in relation to tumor 
prostaglandins. Adv Pro~ Throm Leuk Res 12:299-
301, 1983. 
31 Powles, TJ: Administration of prostaglandin A and 
E and antiinflammatory drugs to patients with 
cancer. Adv Pros Throm Leuk Res 12:327-331, 1983. 
32 Martin CR: Hormone biosynthesis and metabolism. 
33 
Endocrine Physiology. Oxford University Press\New 
York, N.Y., 1,99-134, 1985. . 
Majerus PW, 
Wilson DB: 
platelets. 
Prescott SM, Holfmann SL, Neufeld EJ, 
Uptake and release of arachidonate by 
Adv Pros Throm Leuk Res 11:45-51, 1983. 
34 Samuelsson B: The Leukotrienes: An introduction. 
Adv Pros Throm Leuk Res 9:1-17, 1982. 
35 Andersen NH, Hartzell CJ,-De B: Chemistry and 
structure of cyclooxygenase-derived eicosaniods: A 
historical prespective. Adv Pro Throm Leuk Res 
14:1-43, 1985. 
36 Caton MPL, Hart 
.prostaglandins. 
1985. 
TW: Synthesis of classical 
Adv Pro Throm Leuk Res 14:73-129, 
37 Fontana JA, Miksis G, Miranda DM, Durham JP: 
Inhibition of human mammary carcinoma cell 
proliferation by retiniods and intracellular cAMP-
elevating compounds. JNCI 78:1107-1111, 1987. 
38 Goldyne ME, Stobo JD: T-cell-derived arachidonic 
acid and eicosanoid synthesis by macrophages. Adv 
Pros Throm Leuk Res 12:39-42, 1983. 
39 Kaley'G, Hintze TH, Panzenbeck M, Messina EJ: Role 
of prostaglandins in microcirculatory function. 
Adv Pros Throm Leuk Res 13:27-35, 1985. 
40.. 
40 Poyser NL: Effects of hydrocortisone, oestradiol 
and progesterone on A23187-stimulated prostaglandin 
output from the guinea-pig uterus superfused in 
vitro. Pros 33:101-112, 1987. 
41 Tischler A, Bailey P, Dallob A, Witzel B, Durette 
P, Rupprecht K, Allison D, Dougherty H, Humes J, 
Ham E, Bonney R, Egan R, Gallagher T, Miller D, 
Goldenburg M: L-652,343: A novel dual 5-
lipoxygenease/cclooxygenase inhibito~. Adv Pros 
Throm Leuk Res 16:63-66, 1986. 
42 Coleman RA, Kennedy I, Sheldrick RLG: New evidence 
with selective agonists and antagonists for the 
iubclassification of PGE2-sensitive tEP) ieceptors. 
Adv Pros Throm Leuk Res 17:467-470, 1987. • 
43 Raduchel B, Vorbruggen H: Prostaglandin ana+ogs. 
Adv Pros Throm Leuk Res 14:263-307, 1985. 
44 Toda M, Arai Y, Hayashi M: Analogs of leukotrienes 
and related lipoxygenase products. Adv Pros Throm 
Leuk Res 14:427-436, 1985. 
